Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

NCT00281294 is registered in ClinicalTrials.gov with PDL BioPharma, Inc. as lead sponsor.

NCT NCT00281294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00281294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Lead sponsor
PDL BioPharma, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2005
Completion date
December 31, 2006
Enrollment
40
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid